Russell Investments Group Ltd. Acquires 34,635 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Russell Investments Group Ltd. increased its holdings in Ultragenyx Pharmaceutical by 50.1% during the first quarter, acquiring an additional 34,635 shares.
• A number of institutional investors, including GAMMA Investing LLC and Covestor Ltd., also increased their stakes in Ultragenyx Pharmaceutical in the same period, highlighting growing investor interest.
• Analysts have set a new average target price of $81.50 for Ultragenyx Pharmaceutical, with a consensus rating of "Moderate Buy" after several research updates.

Russell Investments Group Ltd. boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 50.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 103,822 shares of the biopharmaceutical company's stock after acquiring an additional 34,635 shares during the period. Russell Investments Group Ltd. owned 0.11% of Ultragenyx Pharmaceutical worth $3,759,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in RARE. GAMMA Investing LLC increased its position in Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 323 shares during the period. ANTIPODES PARTNERS Ltd bought a new position in Ultragenyx Pharmaceutical during the 1st quarter worth $57,000. Headlands Technologies LLC bought a new position in Ultragenyx Pharmaceutical during the 1st quarter worth $59,000. Covestor Ltd increased its position in Ultragenyx Pharmaceutical by 86.8% during the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock worth $62,000 after buying an additional 795 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in Ultragenyx Pharmaceutical during the 4th quarter worth $82,000. Institutional investors own 97.67% of the company's stock.

Analysts Set New Price Targets

RARE has been the topic of several recent research reports. HC Wainwright upgraded Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price objective on the stock in a research report on Monday, July 28th. William Blair initiated coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. Guggenheim reiterated a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wedbush reduced their target price on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a report on Monday, July 14th. Finally, Canaccord Genuity Group reduced their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Eleven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Stock Up 0.9%

NASDAQ:RARE opened at $29.78 on Friday. The stock's 50-day simple moving average is $31.69 and its 200 day simple moving average is $35.79. The firm has a market capitalization of $2.87 billion, a PE ratio of -5.39 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a twelve month low of $25.81 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same period last year, the firm posted ($1.52) earnings per share. The business's revenue for the quarter was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.